Maze Therapeutics, Inc. (MAZE) Insider Ownership

Based on data from the past 90 days ending January 10, 2026, Maze Therapeutics's three largest insider shareholders are TenPercentOwner Rock Ventures Iv, L.P. Third (5.42Mn shares), Director Jonathan E Lim (307.96K shares), Director Charles J Homcy (38.53K shares).

• A detailed ownership breakdown for Maze Therapeutics is not available at this time.
• At January 10, 2026, insider ownership concentration at Maze Therapeutics equals 16.23% of the company's equity base, encompassing roughly 7.40Mn shares from 45.59Mn total outstanding.
• Maze Therapeutics's count of insider shares amounted to 7.40Mn as of January 10, 2026.
• As of January 10, 2026, President And R&D & Cmo Harold Bernstein recorded the highest insider purchase activity at Maze Therapeutics, accumulating 75.00K shares during the past 90 days.
• As of January 10, 2026, TenPercentOwner Rock Ventures Iv, L.P. Third executed the most significant insider divestiture at Maze Therapeutics, disposing of 1.60Mn shares over the last 90-day period.